



Fresenius Medical Care

The World's Leading Renal Therapy Company

Commerzbank Sector Conference

Frankfurt/Main, August 23, 2010



Fresenius Medical Care



Forward-looking Statements


Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

1. Business Update

2. Financials and Outlook

3. Global Leadership Position

4. Growth Strategy and Summary




1. Business Update

2. Financials and Outlook

3. Global Leadership Position

4. Growth Strategy and Summary





Strong quarter and fully on track for full-year targets

Very good underlying performance

	Q2 2009	Q2 2010	Growth
Revenue	\$ 2,764 m	\$ 2,946 m	7%
Net income <small>attributable to FMC AG & Co. KGaA</small>	\$ 221 m	\$ 248 m	12%
Earnings per share	\$ 0.74	\$ 0.83	12%


- Strong revenue growth at 7% at constant currency and 6% organic
- Excellent EBIT-margin development
- Resulting in very good net income growth



Total revenue increased 7% to \$2,946 m

North America	
Revenue	\$2,027 m
Growth actual	8%
Growth organic	7%

International	
Revenue	\$919 m
Growth cc	5%
Growth organic	3%



Latin America	
Revenue	\$141 m
Growth	15% / 8% cc

Asia-Pacific	
Revenue	\$176 m
Growth	12% / 5% cc

Europe	
Revenue	\$602 m
Growth	-1% / 4% cc

cc = constant currency




First Half 2010 – Revenue

Total revenue increased 9% to \$5,828 m

North America	
Revenue	\$3,986 m
Growth actual	9%
Growth organic	8%

International	
Revenue	1,842 m
Growth cc	6%
Growth organic	4%



Latin America	
Revenue	\$281m
Growth	20% / 9% cc

Europe	
Revenue	\$1,224 m
Growth	7% / 5% cc

Asia-Pacific	
Revenue	\$337 m
Growth	16% / 7% cc

cc = constant currency



Very strong revenue growth globally

First time over 200,000 patients being treated

US\$ millions	Q2 2009	Q2 2010	Growth	cc
North America	1,677	1,817	8%	
International	377	407	8%	9%
Total	2,054	2,224	8%	8%

- Good organic treatment growth of 4.3% globally
- Continued strong revenue per treatment development
- Treating 202,414 patients in 2,599 clinics

cc = constant currency

First Half 2010 – Dialysis Services Global

Very strong revenue growth globally

US\$ millions	H1 2009	H1 2010	Growth	cc
North America	3,254	3,578	10%	
International	723	817	13%	9%
Total	3,977	4,395	11%	10%

- Good organic treatment growth of 4.3% globally
- Continued strong revenue per treatment development

cc = constant currency



Overall strong quality performance

	North America (USA)		EMEA	
% of patients	Q2 2009	Q2 2010	Q2 2009	Q2 2010
Kt/V ≥ 1.2	96%	96%	95%	95%
Hemoglobin = 10-12 g/dl	64%	68%	54%	54%
Albumin ≥ 3.5 g/dl	82%	81%	88%	86%
Phosphate 3.5-5.5 mg/dl	52%	55%	61%	61%
Hospitalization days	10.1	9.9	8.5	9.2

* The hospitalization rates for the US reflects adoption of CMS policy



Very good performance in all key metrics


Q2 2010	Total	North America	International
Organic revenue growth	7%	7%	5%
Same market treatment growth	4.3%	4.2%	4.4%
Revenue per treatment		\$349 ¹⁾	\$159
June 30, 2010			
Number of clinics	2,599	1,795	804
Growth	5%	4%	9%
De novos	45	28	17

1) including Mexico

cc = constant currency



Stable reimbursement environment





Good product growth in North America

US\$ millions	Q2 2009	Q2 2010	Growth	cc
Total revenue (incl. internal revenue)	955	994	4%	5%
External revenue	709	722	2%	3%
North America	199	210	5%	
International	510	512	0%	2%

cc = constant currency

First Half 2010 – Dialysis Products

Good product growth in H1 2010

US\$ millions	H1 2009	H1 2010	Growth	cc
Total revenue <small>(incl. internal revenue)</small>	1,813	1,962	8%	6%
External revenue	1,346	1,433	6%	4%
North America	396	408	3%	
International	950	1,025	8%	4%

cc = constant currency

CMS published final bundle rule on July 26, 2010

Key Components	September 2009	Published July 26, 2010
1. Adjusted base rate	\$198/Rx	\$229/Rx
2. ESRD related Oral only drugs	In bundle 2011 \$14/Rx	In bundle 2014 Payment to be established
3. Transition	3%	3.1% may prospectively update analysis for 2012
4. Ownership adjuster	CMS <u>may</u> include an adjuster based on type of facility ownership	CMS did <u>not</u> include an adjuster based on type of facility ownership
5. Laboratory Tests	Considered	Specified list of laboratory tests included
6. Home Care Training adjuster	Considered	CMS creates home or self-care dialysis training adjustment

Expanded Dialysis Services and Products in Key Regions



- ▶ Acquired Asia Renal Care
 - ▶ Adding more than 100 clinics treating about 6,200 patients
 - ▶ Adding approximately \$80 million in annual revenue
- ▶ Expanded dialysis products business in Korea
 - ▶ Adding approximately \$15 million in annual revenue
 - ▶ Accretive to earnings in the first year
- ▶ Entered into long-term distributor agreement in Japan



- ▶ Expanded dialysis services business in Russia
 - ▶ Adding approximately \$25 million in annual revenue
 - ▶ Accretive to earnings in the first year



Superior quality performance in both products and services

Continued focus on R&D - new products and therapies worldwide

Strong underlying operational performance

Excellent cash flow development


Reiterated full-year guidance 2010

1. Business Update

2. Financials and Outlook

3. Global Leadership Position

4. Growth Strategy and Summary



2nd Quarter 2010 – Profit & Loss



US\$ millions	Q2 2009	Q2 2010	Growth
Net revenue	2,764	2,946	7%*
Operating income (EBIT)	418	465	11%
EBIT margin in %	15.1	15.8	
Interest expense, net	76	68	
Income before income tax	342	397	16%
Income tax expense	103	129	
Tax rate	30%	33%	
Non-controlling interest	18	20	
Net income attributable to FMC AG & Co. KGaA	221	248	12%

* 7% growth at constant currency, 6% organic growth






First Half 2010 – Profit & Loss

US\$ millions	H1 2009	H1 2010	Growth
Net revenue	5,323	5,828	9%*
Operating income (EBIT)	813	888	9%
EBIT margin in %	15.3	15.2	
Interest expense, net	149	135	
Income before income tax	664	753	13%
Income tax expense	214	257	
Tax rate	32%	34%	
Non-controlling interest	31	37	
Net income attributable to FMC AG & Co. KGaA	419	459	10%

* 8% growth at constant currency, 7% organic growth




Operating Margin Development





Days Sales Outstanding (DSO)

Continued excellent cash collection





Strong operating cash flow performance

US\$ millions	Q2 2009	Q2 2010	Growth
Operating cash flow ¹⁾	282	294 10% of revenue	4%
Capital expenditures, net ¹⁾	(139)	(119)	
Free cash flow	143	175 6% of revenue	23%
Acquisitions, net of divestitures ^{1) 2)}	(45)	(68)	
Free cash flow, after acquisitions ^{1) 2)}	98	107	

1) A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

2) Does not include a \$133 m cash out for a short-term bank deposit in Q2 2010 and a cash repayment in form of an inter-company loan of \$ 50 m in Q2 2009

First Half 2010 – Cash Flow

Operating cash flow at 11% of revenue



US\$ millions	H1 2009	H1 2010	Growth
Operating cash flow ¹⁾	437	643 11% of revenue	47%
Capital expenditures, net ¹⁾	(249)	(218)	
Free cash flow	188	425 7% of revenue	127%
Acquisitions, net of divestitures ^{1) 2)}	(81)	(150)	
Free cash flow, after acquisitions ^{1) 2)}	107	275	

1) A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

2) Does not include a \$133 m cash out for a short-term bank deposit in Q2 2010 and a cash repayment in form of an inter-company loan of \$ 50 m in Q2 2009



Debt/EBITDA ratio ahead of target



* including non-cash charges and in 2007 excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics. A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

2010 – Outlook Reiterated



Fully on track for 2010 Targets

US\$ millions

Net revenue

Net income

attributable to FMC AG & Co. KGaA

Leverage ratio

(Debt/EBITDA)

Capital expenditures

Acquisitions

Updated

GUIDANCE

> \$12,000

\$950 - 980

< 2.5

~ \$550 - 650

up to \$500



1. Business Update

2. Financials and Outlook

3. Global Leadership Position


4. Growth Strategy and Summary



Global Presence Products & Services



Fresenius Medical Care




Dialysis Services Worldwide – Number of Patients Treated 2009*




Fresenius Medical Care

North America




EMEA




**\$65
Billion
Market**

**We Lead in Every Major
Market, Treating more
than 195,000 Patients
Worldwide**

Latin America




Asia Pacific




* Based on company statements and estimates

** 13,606 patients including managed clinics

1,895,000 Dialysis Patients in 2009



Dialysis patients treated in 2009 by company




Market Position by Major Product Groups



	<u>Rank 1</u>	<u>Rank 2</u>	<u>Rank 3</u>
Dialyzers	FME	Gambro	Nipro
Dialysis machines	FME	Gambro	Nikkiso
Hemodialysis concentrates	FME	Fuso	Gambro
Bloodlines	FME	Gambro	Kawasumi
Peritoneal dialysis products	Baxter	FME	Pisa

Dialyzers



Dialysis machines




Produced more than ~85,000,000 Dialyzers in 2009

1. Business Update

2. Financials and Outlook

3. Global Leadership Position


4. Growth Strategy and Summary





Global prevalence increased by 80% over the last 10 years

ESRD patients per million population (p.m.p.)



Dialysis Patients 1,895,000

Hemodialysis 1,692,000 (89%)

Peritoneal Dialysis 203,000 (11%)



Services – Reduction in Mortality

North America 2005 – 2009: 21%

Europe 2005 – 2009: 13%

Products – Bloodlines


**Reynosa, Mexico 2002 – 2010:
85% Improvement in Quality**

**Achieved less than 3 complaints per million while
producing 73 million bloodlines per year**

Development of Dialysis Patient Numbers



Fresenius Medical Care



- Renal failure persists worldwide
- Dialysis is the primary treatment modality on a global scale
- The number of global dialysis patients is expected to double by 2020



Integrated Care

Therapy

Renal
Drugs



Patient Care

Products



4008S



2008K



5008S



SleepSafe



Liberty Cyclor



Our global presence, growth and profitability is market leading

Vertical integration was and will be the best business model

There are many opportunities but also challenges

We will confidently continue to pursue our growth strategy, and we will remain vigilant with respect to:

Quality

Innovation

Corporate Ethics



**Thank you for your interest in
Fresenius Medical Care !**





Fresenius Medical Care

The World's Leading Renal Therapy Company

Commerzbank Sector Conference

Frankfurt/Main, August 23, 2010



Fresenius Medical Care



Reconciliation of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measure

All figures are in \$ millions

Debt	Q2 2010	FY 2009	FY 2008	FY 2007
Short-term borrowings (incl. A/R program)	410	316	684	217
+ Short-term borrowings from related parties	9	10	1	2
+ Current portion of long-term debt and capital lease obligations	1,866	158	455	85
+ Current portion of trust preferred securities				670
+ Long-term debt and capital lease obligations, less current portion	2,949	4,428	3,957	4,004
+ Trust preferred securities	593	656	641	664
= Total debt	5,827	5,568	5,738	5,642

EBITDA	Q2 2010	FY 2009	¹⁾ FY 2008	FY 2007
Last twelve months operating income (EBIT)	1,830	1,756	1,672	1,580
+ Last twelve months depreciation and amortization	487	457	416	363
+ Non-cash charges	49	50	44	41
= EBITDA (annualized)	2,366	2,263	2,132	1,984

Capital expenditure (net)	H1 2010	H1 2009	Q2 2010	Q2 2009
Purchase of property, plant and equipment	(227)	(254)	(121)	(142)
- Proceeds from sale of property, plant and equipment	9	5	2	3
= Capital expenditure (net)	(218)	(249)	(119)	(139)

1) Excluding restructuring costs and in-process R&D

Attachment II



Reconciliation of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measure

All figures are in \$ millions

External Revenue	H1 2010	H1 2009	Growth	cc	Q2 2010	Q2 2009	Growth	cc
International product revenue	1,207	1,109	9	5	604	595	1	2
- Internal revenue	(182)	(159)	15		(92)	(85)	8	
= External revenue	1,025	950	8	4	512	510	0	2
North America product revenue	755	704	7		390	360	8	
- Internal revenue	(347)	(308)	12		(180)	(161)	12	
= External revenue	408	396	3		210	199	5	
TOTAL product revenue	1,962	1,813	8	6	994	955	4	5
- Internal revenue	(529)	(467)	13		(272)	(246)	11	
= External revenue	1,433	1,346	6	4	722	709	2	3

Acquisitions (net)	H1 2010	H1 2009	Q2 2010	Q2 2009
Acquisitions and investment and net purchases of intangible assets	(291)	(82)	(207)	(45)
Proceeds from divestitures	8	51	6	50
Acquisitions and investments, net of divestitures	(283)	(31)	(201)	5
Investment, net of repayments	133	(50)	(133)	(50)
Acquisitions, net of divestitures	(150)	(81)	(68)	(45)

cc = constant currency

Dialysis Services - Global

Q2 2010	Clinics	Patients	Treatments (in millions)
Total	2,599	202,414	15.3
Growth	+ 5%	+ 6%	+ 6%
North America	1,795	135,088	10.2
Growth	+ 4%	+ 5%	+ 6%
International	804	67,326	5.0
Growth	+ 9%	+ 11%	+ 8%
Europe	463	35,277	2.6
Latin America	193	21,761	1.7
Asia-Pacific	148	10,288	0.8




First Half 2010 – Overview

	H1 2009	H1 2010	Growth
Revenue	\$ 5,323 m	\$ 5,828 m	+9%
Net income <small>attributable to FMC AG & Co. KGaA</small>	\$ 419 m	\$ 459 m	+10%
Earnings per share	\$ 1.41	\$ 1.53	+9%


- Strong revenue growth at 8% at constant currency and 7% organic
- Continued excellent cash flow development



H1 2010 Operating Margin Development



CMS annual costs per ESRD patient – \$87,400





Fresenius Medical Care AG & Co. KGaA
Investor Relations
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.

Ordinary shares

WKN 578 580
ISIN DE0005785802
SEDOL1 5129074 DE

Oliver Maier
Head of Investor Relations & Corporate Communications

Tel.: +49-(0)6172-609-2601
Fax.: +49-(0)6172-609-2301
E-mail: oliver.maier@fmc-ag.com

Gerrit Jost
Tel.: +49-(0)6172-609-5216
Fax.: +49-(0)6172-609-2301
E-mail: gerrit.jost@fmc-ag.com

Terry L. Morris
Tel.: +1-800-948-2538
Fax.: +1-615-345-5605
E-mail: terry.morris@fmc-na.com



- Capital Market Day** – **September 1-2, 2010, London, UK**
- Q3 2010 Results** – **Conference Call, November 2, 2010**

For recent updates, please have a look at our website.

www.fmc-ag.com

Calendar

Investor Relations > Financial Calendar

Annual Report / Quarterly Filings / SEC Filings / Deutsche Börse Filings ...

Investor Relations > Publications

Corporate Governance / Sarbanes-Oxley Act / NYSE declaration ...

Investor Relations > Corporate Governance

Financing / Analyst Coverage / Consensus estimates / Share data ...

Investor Relations > Our Shares



Fresenius Medical Care

The World's Leading Renal Therapy Company

Commerzbank Sector Conference

Frankfurt/Main, August 23, 2010



Fresenius Medical Care